New research by academics at the University of Leicester published today (Friday 25th June) has given fresh hope to patients with type 2 diabetes, after Eli Lilly and Company’s SURPASS-2 clinical trial showed that 60% of patients achieved a 10% percent or greater weight loss with 15 mg of the medicine tirzepatide after four weeks.Read More
Funding for a five-year project, that aims to develop a new type of care package that addresses gaps in support for people under 40 living with type 2 diabetes, has been awarded to a research team in Leicester.
Hard to reach is the term often used to describe people who don’t want to come to ‘town hall’ style meetings, academic talks or committees. It’s a term increasingly and rightly out of fashion, as researchers in universities and hospitals develop sufficient awareness to realise that it’s the institution and the nature of its engagement that is hard to reach. It’s a term I’ve always found absurd, in light of the simple fact that I don’t want to go to committees or town hall style meetings or academic talks outside of work hours myself!Read More
Patients with type 2 diabetes that were treated with a weekly injection of the breakthrough drug Semaglutide were able to achieve an average weight loss of nearly 10kg, according to a new study published in The Lancet today.Read More
Previous research in diabetes led by Leicester researchers has played a key role in laying foundations for new breakthrough in weight-loss treatment.Read More
Adults with type 2 diabetes that have no history, signs or symptoms of heart problems have been shown to have severely limited exercise capacity, according to researchers at the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. Such limitations place them at impending risk of developing heart failure, according to the team who led the study.Read More